Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Assets Average: 2011-2025

Historic Assets Average for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Sep 2025 value amounting to $1.4 billion.

  • Arrowhead Pharmaceuticals' Assets Average rose 36.69% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 36.69%. This contributed to the annual value of $1.3 billion for FY2025, which is 32.53% up from last year.
  • Arrowhead Pharmaceuticals' Assets Average amounted to $1.4 billion in Q3 2025, which was down 6.37% from $1.5 billion recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Assets Average high stood at $1.5 billion for Q2 2025, and its period low was $628.0 million during Q1 2021.
  • Moreover, its 3-year median value for Assets Average was $919.5 million (2024), whereas its average is $1.0 billion.
  • Its Assets Average has fluctuated over the past 5 years, first fell by 12.10% in 2023, then skyrocketed by 63.60% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Assets Average stood at $674.3 million in 2021, then rose by 17.41% to $791.7 million in 2022, then fell by 12.10% to $695.9 million in 2023, then skyrocketed by 54.72% to $1.1 billion in 2024, then skyrocketed by 36.69% to $1.4 billion in 2025.
  • Its Assets Average stands at $1.4 billion for Q3 2025, versus $1.5 billion for Q2 2025 and $1.3 billion for Q1 2025.